Gilead plots trial of groundbreaking, once-a-year HIV prevention drug lenacapavir
Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.
Health and Me on MSN11d
Japan Could Become The First Country To Eradicate HIV
The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of ...
pharmaphorum8d
Gilead will challenge US government patent on PrEP drug Truvada
Gilead Sciences has said it plans to challenge patents held by the US government on the use of its HIV drug Truvada for pre-exposure prophylaxis (PrEP). In a move that will incense critics who ...
Business Wire28d
U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
U.S. full Prescribing Information for Truvada, including Boxed Warning, and lenacapavir are available at www.gilead.com. Gilead and the Gilead logo, Truvada, and Truvada for PrEP are registered ...
Nasdaq7d
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
U.S. full Prescribing Information for Truvada, including Boxed Warning, and lenacapavir are available at www.gilead.com. Gilead and the Gilead logo, Truvada, and Truvada for PrEP are registered ...
Business Wire22d
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
U.S. full Prescribing Information for Truvada, including Boxed Warning, and lenacapavir are available at www.gilead.com. Gilead and the Gilead logo, Truvada, and Truvada for PrEP are registered ...
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
HIV Drugs Market Outlook: Future Trends Indicate a US$ 47.5 Billion Industry by 2034 with a Shift Toward Single-dose Regimens | Report by TMR
The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...
Barchart on MSN4d
Gilead Sciences - Leader in HIV Medicines
Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...
Gilead presents data for once-yearly lenacapavir for HIV prevention
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Yahoo Finance28d
Gilead’s lenacapavir moves closer to FDA approval for HIV PrEP use
Gilead is edging closer to an approval for its twice-yearly injectable human immunodeficiency virus-1 (HIV-1) capsid inhibitor, lenacapavir, as a pre-exposure prophylaxis (PrEP) option. The US ...